We were proud to present promising updated preliminary data from our wholly owned Fabry study, to resume our partnered Hemophilia A pivotal trial, and to continue dosing in our renal transplant rejection and sickle cell studies. I interviewed at Sangamo Therapeutics in Aug 2020, Nice set of interviews and great questions. ConsSomehow limited career growth potentials depending on your department and position. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Fabry disease Reported data updates from the Phase 1/2 STAAR studys dose escalation phase; Dose expansion phase underway and dosing commenced; Phase 3 planning progresses. Dosing of the next patient is anticipated in the third quarter of 2022. Background and experience. Under the general direction of the EHS Director, this role will have operational responsibility for EHS support to labs, facilities and manufacturing and shall assist with planning, establishing, implementing, and maintaining a variety of occupational health, safety, and . Coworkers are all very helpful and friendly. Three weeks. Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. This non-GAAP financial measure is in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. Lower level growth in scientific thinking can be improved. Sangamo is a genomic medicine company that seeks to help millions of people who suffer from severe diseases for which today's medicine can only offer symptom management at best. The conference call dial-in numbers are (877) 377-7553 for domestic callers and (678) 894-3968 for international callers. This employer has claimed their Employer Profile and is engaged in the Glassdoor community. Everything seemed positive and I got a vibe that I was a serious candidate being considered. This is based on anonymous employee . I interviewed at Sangamo Therapeutics in Aug 2020, Nice set of interviews and great questions. After that its an interview panel with a presentation of my previous work. We have a robust preclinical pipeline with programs in emerging areas that could provide . Sangamo Therapeutics Inc (NASDAQ: SGMO) announced updated preliminary data as of October 20, 2022, the cutoff date from the Phase 1/2 STAAR study of isaralgagene civaparvovec, or ST-920, a wholly. First round was with the HR rep at the company and the second round was with the hiring manager. Consolidated net loss for the third quarter ended September 30, 2022 was $53.2 million, or $0.34 per share, compared to a net loss of $47.7 million, or $0.33 per share, for the same period in 2021. Overall, 89% of employees would recommend working at Sangamo Therapeutics to a friend. Renal Transplant Rejection Received Orphan Medicinal Product Designation from the European Commission; progressed manufacturing and clinical activities ahead of anticipated Q3 dosing. February 27, 2023 9:47 am. media@sangamo.com, Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results, https://www.businesswire.com/news/home/20221103005505/en/, Net loss attributable to non-controlling interest, Basic and diluted net loss per share attributable to, Shares used in computing basic and diluted net loss per share attributable to, Cash, cash equivalents, and marketable securities, Presented updated preliminary data from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, our wholly owned gene therapy product candidate for the treatment of Fabry Disease at three separate conferences, most notably at the 29th. Some details of my previous projects. We continue to actively prepare for a potential pivotal Phase 3 trial. 38% of job seekers rate their interview experience at Sangamo Therapeutics as positive. A pivotal data readout is estimated in late 2023 or early 2024. Super friendly working environment and very nice people. Employees also rated Sangamo Therapeutics 4.1 out of 5 for work life balance, 4.5 for culture and values and 3.8 for career opportunities. We expect to present additional clinical updates from the STAAR study, including the first data from the expansion cohort, in the first half of 2023. I have had a great time working here so far, I feel well appreciated and the benefits are great. Winning Companies champion board diversity by having 20% or more of their board seats held by women. Coupled with strong advances in our preclinical pipeline, we believe this progress positions us well to advance the development of potentially transformational genomic medicines for patients in need and to generate long-term value for our shareholders.. However, after the last interview I haven't heard back from them. Our platforms have yielded multiple clinical stage programs that could provide value in the near-to-mid-term. 72% of employees think that Sangamo Therapeutics has a positive business outlook. However, I never hear back from them since then. - Achieved 78% globotriaosylceramide (Gb3) substrate clearance at 6-months and 77% reduction in urine podocyte loss in one of, BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 21, 2023-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company is scheduled to hold a conference call on Wednesday, February 22, 2023 at 4:30 p.m. Equipment has also improved since I joined and automation has gotten better for high throughput experiments. We have excluded stock-based compensation expense because it is a non-cash expense that may vary significantly from period to period as a result of changes not directly or immediately related to the operational performance for the periods presented. Duties of the advertised position and the involved project. When did GD start to be awful? Supervisors are flexible. We have a robust preclinical pipeline with programs in emerging areas that could provide value in the mid-to-long term. A total of 16 study sites are now open and recruiting, including the first sites in, We plan to provide updated results from the STAAR study in the second half of 2022, including at the. Total operating expenses on a GAAP basis for the second quarter ended June 30, 2022, were $75.1 million, compared to $76.6 million for the same period in 2021. I think it depends what you prioritize in a workplace, benefits, etc. The interview was timely, provided an overview of the company and of the role, asked the candidate to go over their relevant career trajectory and competences. All patients withdrawn have remained off ERT. These risks and uncertainties are described more fully in our Securities and Exchange Commission filings and reports, including in our Annual Report on Form 10-K for the year ended December 31, 2021 as supplemented by our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022.
Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. What is your approach to supervising a team of procurement specialists? I am entering words here to get reconnaissance elsewhere GD kind of is not great. The average Sangamo Therapeutics salary ranges from approximately $88,067 per year for a Research Associate II to $240,483 per year for an Associate Director. Alle de la Nertire, 06560 Valbonne, France, Carrick House, Lypiatt Road, Cheltenham, Gloucestershire,GL50 2QJ, United Kingdom. As we look to next year and beyond, I am confident in Sangamos ability to carry out our mission of developing transformational therapies for patients in need.. This is based on 44 anonymously submitted reviews on Glassdoor. Our ability to fund our projects enables us to execute and deliver on our mission. ProsGreat science and robust pipelines. Working in the company was very fun, I learned a lot about the technology that the company uses and about the different methodologies and techniques Sangamo has. Cash, cash equivalents and marketable securities as of June 30, 2022, were $363.7 million, compared to $464.7 million as of December 31, 2021. Actual results may differ materially from those projected in these forward-looking statements due to the risks and uncertainties described above and other risks and uncertainties that exist in the operations and business environments of Sangamo and our collaborators. Technical assay related questions? Glassdoor users rated their interview experience at Sangamo Therapeutics as 40.0% positive with a difficulty rating score of 2.86 out of 5 (where 5 is the highest level of difficulty). Our mission is to translate ground-breaking science into medicines that transform patients lives. HR screen is just going over the Job Description and why Sangamo. Analyst Report: Alnylam Pharmaceuticals, Inc. Analyst Report: BioMarin Pharmaceutical Inc. NasdaqGS - NasdaqGS Real Time Price. I am able to speak with VPs of many different departments with ease. How many more words to count? Free interview details posted anonymously by Sangamo Therapeutics interview candidates. Sangamo is a genomic medicine company that seeks to help millions of people who suffer from severe diseases for which todays medicine can only offer symptom management at best. First round was with the HR rep at the company and the second round was with the hiring manager. Conference Call to Discuss Third Quarter 2022 Results. A replay will be available following the conference call, accessible under Events and Presentations. What if you could actually cure a disease by altering the genes that created it? Candidates applying for Contractor had the quickest hiring process (on average 1 day), whereas Project Manager roles had the slowest hiring process (on average 120 days). Tell me about yourself? This is based on anonymous employee reviews submitted on Glassdoor. ET to review its fourth quarter and full year 2022. See 1 answer. This rating has improved by 1% over the last 12 months. Sangamo Therapeutics has an overall rating of 4.2 out of 5, based on over 55 reviews left anonymously by employees. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. 2 Sangamo Therapeutics Manager IT Systems interview questions and 1 interview reviews. Our scientists are leaders in the. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the effects of the evolving COVID-19 pandemic and the impacts of the pandemic and other macroeconomic factors, including as a result of the ongoing conflict between Russia and Ukraine, on the global business environment, healthcare systems and business and operations of Sangamo and our collaborators, including the initiation and operation of clinical trials; the research and development process, including the enrollment, operation and results of clinical trials and the presentation of clinical data; the uncertain timing and unpredictable nature of clinical trial results, including the risk that therapeutic effects in the Phase 3 AFFINE trial will not be durable in patients as well as the risk that the therapeutic effects observed in the latest preliminary clinical data from the Phase 1/2 STAAR study and the Phase 1/2 PRECIZN-1 study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civaparvovec, or BIVV003 (formerly known as SAR44513); the unpredictable regulatory approval process for product candidates across multiple regulatory authorities, including the potential that health authorities will not issue the required protocol amendment approvals in the Phase 3 AFFINE trial in a timely manner, or at all; reliance on results of early clinical trials, which results are not necessarily predictive of future clinical trial results, including the results of any Phase 3 trial of our product candidates; our limited experience manufacturing biopharmaceutical products, including the risks that we may be unable to maintain compliant manufacturing facilities, build additional facilities and manufacture our product candidates as intended; the potential for technological developments that obviate technologies used by Sangamo; the potential that Sangamo will not be able to identify and secure options or new collaborators for the BIVV003 program; the potential for Sangamo to cease development of the BIVV003 program, whether due to its inability to secure options to advance the program or otherwise;our lack of resources to fully develop, obtain regulatory approval for and commercialize our product candidates; and our ability to achieve expected future financial performance. Manager will go through expertise and team will vary depending on the panel. While not required, it is recommended you join 10 minutes prior to the event start. Questions asked were appropriate and aimed at confirming the candidate possesses the required skills and would be a good fit into the company. These risks and uncertainties are described more fully in our Securities and Exchange Commission filings and reports, including in our Annual Report on Form 10-K for the year ended December 31, 2021, as supplemented by our Quarterly Report on Form 10-Q for the quarter ended September 30, 2022. The decrease in total operating expenses on a GAAP basis was primarily due to the timing of certain research and development activities. Sangamo was founded in 1995 as Sangamo BioSciences, Inc. in order to research new technologies for genome editing. Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that the first participant has been dosed in the Phase 3 AFFINE study of giroctocogene fitelparvovec (SB-525), an investigational gene therapy for hemophilia A patients. Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time. Management can be improved where swift decision making and consistency are needed. Nothing striking about this particular process. Pfizer advised us that it continues to anticipate resuming the dosing of additional patients in the Phase 3 AFFINE trial of giroctocogene fitelparvovec, an investigational gene therapy we are developing with Pfizer for patients with moderately severe to severe hemophilia A, in the third quarter of 2022. There are no open jobs at Sangamo Therapeutics, Inc. currently. Duties of the advertised position and the involved project. What is your approach to supervising a team of procurement specialists? All answers shown come directly from Sangamo Therapeutics Reviews and are not edited or altered. However, after the last interview I haven't heard back from them. Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. How is diversity at Sangamo Therapeutics? While not required, it is recommended you join 10 minutes prior to the event start. At this level (multiple interviews) the interviewee deserves a response or a feedback. For Sangamo Therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. Received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for BIVV003. Guided by Science. I wasn't happy with the unprofessional manner. Would never interview here again, HR screen, Manager, Team. The process took 4 weeks. Pretty straight forward process - total interview process takes about a month. Common stages of the interview process at Sangamo Therapeutics according to 17 Glassdoor interviews include: Find a Great First Job to Jumpstart Your Career, Stand Out From the Crowd With the Perfect Cover Letter, How to Prepare for Your Interview and Land the Job. Good, great, fine, virtual, lovely. We completed manufacturing of the dose for the second patient, who recently received a kidney transplant. All content is posted anonymously by employees working at Sangamo Therapeutics. Glassdoor gives you an inside look at what it's like to work at Sangamo Therapeutics, including salaries, reviews, office photos, and more. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Apr 28, 2022 - Principal Research Associate, May 10, 2022 - Senior Development Engineer, Sangamo Therapeutics has an overall rating of 4.2 out of 5, based on over 55 reviews left anonymously by employees. It was then followed by individual interviews with different members of the team, To get a job at Sangamo Therapeutics, browse, Overall, 89% of employees would recommend, Work Here? I applied through college or university. Consolidated net loss for the second quarter ended June 30, 2022, was $43.2 million, or $0.29 per share, compared to a net loss of $47.2 million, or $0.33 per share, for the same period in 2021. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided, or to use the dial-out option to connect their phone instantly. Sickle cell disease Dosed sixth patient, the second with a product candidate manufactured using improved methods; Phase 3 planning progresses. Pioneering the future of genomic medicine, Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results, Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease, Phase 3 Trial of Investigational Gene Therapy for Hemophilia A has Resumed Dosing, Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated -Gal A Enzyme Activity in Nine Patients, Pfizer and Sangamo Therapeutics Announce Phase 3 Trial of Investigational Gene Therapy for Hemophilia A has Re-opened Recruitment, European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ Transplantation, First-in-human in vivo genome editing via AAV-zinc finger nucleases for mucopolysaccharidosis I/II and hemophilia B, Regulatory Consideration for the Nonclinical Safety Assessment of Gene Therapies, Poster: STAAR, a Phase 1/2 study of isaralgagene civaparvovec (ST 920) gene therapy in adults with Fabry disease, Presentation: STAAR, a Phase 1/2 study of isaralgagene civaparvovec (ST 920) gene therapy in adults with Fabry disease. Filler, words, noun, verb, et cetera. The Phase 1/2 STAAR study has transitioned into the expansion phase, with the first five expansion patients dosed at the 5e13 vg/kg dose level, including the first two female patients. Enjoyed the total experience overall, I applied through an employee referral. Be the first to find this interview helpful. General high turnover rate in biotech industry applies here as well. The product candidate continues to be generally well tolerated in both patients. I interviewed at Sangamo Therapeutics (San Francisco, CA) in Aug 2020. Glassdoor has millions of jobs plus salary information, company reviews, and interview questions from people on the inside making it easy to find a job thats right for you. We completed the transition of Sanofis rights and obligations under the collaboration developing BIVV003, formerly known as. Financial Guidance for 2022 Narrowed (initial guidance provided on February 24, 2022). Reviews 5.0 1 reviews 5.0 Career Growth 5.0 Work - Life Balance 4.0 Compensation / Benefits 5.0 Company Culture 4.0 Management POPULAR 4.0 "Great overall biotech company" Candidates give an average difficulty score of 2.8 out of 5 (where 5 is the highest level of difficulty) for their job interview at Sangamo Therapeutics. We continue to expect non-GAAP total operating expenses, excluding estimated non-cash stock-based compensation expense of approximately $40 million, in the range of approximately $280 million to $310 million in 2022. Patient dosing is expected to resume in October New York, NY, and Brisbane, California, September 22, 2022 - Pfizer and Sangamo Therapeutics announced that the Phase 3 AFFINE study evaluating giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A, has re-opened recruitment. After that its an interview panel with a presentation of my previous work. There can be no assurance that we and our collaborators will be able to develop commercially viable products. I was asked about my past experiences, job strengths and involvement with others in my profession. Four patients were withdrawn from enzyme replacement therapy (ERT) and maintained significantly elevated levels of -Gal A activity up to 28 weeks post withdrawal. Phase 3 enabling activities and manufacturing readiness are in progress. There can be no assurance that we and our collaborators will be able to develop commercially viable products. I applied online. Cash, cash equivalents and marketable securities as of September 30, 2022, were $350.3 million, compared to $464.7 million as of December 31, 2021. Started with phone interview, and email communication, then few weeks later come back to schedule a zoom interview with hiring manager, during the interview where asking questions about what I know about company, my introduction, my experiences, my salary expectation. Hemophilia A Pfizer advised us that it continues to expect resumption of dosing in Q3 2022; pivotal data read-out expected in late 2023 or early 2024. Due to the split at Richmond and Brisbane, there was confusion on which site to interview. Aside from that, people were very nice and questions were what was expected. Were pioneering the future of genomic medicine, Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results, Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease. To supplement our financial results and guidance presented in accordance with GAAP, we present non-GAAP total operating expenses, which exclude stock-based compensation expense from GAAP total operating expenses. This rating has been stable over the past 12 months. Cash, cash equivalents and marketable securities. According to reviews on Glassdoor, employees commonly mention the pros of working at Sangamo Therapeutics to be benefits, career development, culture and the cons to be senior leadership, compensation, management. We believe that this non-GAAP financial measure, when considered together with our financial information prepared in accordance with GAAP, can enhance investors and analysts ability to meaningfully compare our results from period to period and to our forward-looking guidance, and to identify operating trends in our business. BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 3, 2022-- Working in the company was very fun, I learned a lot about the technology that the company uses and about the different methodologies and techniques Sangamo has. Sangamo Therapeutics saw global potential for TxCell's lead candidate TX200 as the anchor of a pipeline of chimeric antigen receptor . Fabry disease Received endorsement to progress into the Ph1/2 studys expansion phase; continued to recruit patients and activate sites; Phase 3 planning progresses. Presented seven posters and one oral presentation at ASGCT on. Barclays Gene Editing & Gene Therapy Summit. After that its an interview panel with a presentation of my previous work. Sangamo Therapeutics, Inc.(Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and third quarter 2022 financial results. A pivotal readout is expected in the first half of 2024. Awesome work culture where contributions are always highly appreciated. These decreases were partially offset by a $1.9 million adjustment to revenue during 2021 related to the collaboration agreement with Sanofi and an increase of $0.5 million in revenue related to our collaboration agreement with Kite. This press release features multimedia. We are passionate about our science and driven by the purpose it serves. Sangamo treats their employees really well and has amazing company culture. Technical assay related questions? Some details of my previous projects. https://www.openpr.com/news/2771399/hemophilia-market-to-showcase-robust-growth-in-the-upcoming-year, https://www.catholicglobe.org/global-mrna-vaccine-market-insight-size-and-forecast/. Sickle cell disease Completed transition of program back to Sangamo; advanced manufacturing activities in anticipation of dosing in Q3; Phase 3 planning progresses. Pros & Cons are excerpts from user reviews. Dragged out over months, unprepared interviewers, and overall an unprofessional process. Was told I was a candidate in the running but they never got back to me and never responded to multiple calls or emails, Anonymous Interview Candidate in San Francisco, CA, I applied online. Claim your Free Employer Profile. Based on 2 interviews. I interviewed at Sangamo Therapeutics in Jan 2021. It was well thought out and carried out professionally. We are committed to translating ground-breaking science into genomic therapies that transform patients lives. Sangamo uses its deep scientific expertise and proprietary zinc finger technology to create genomic cures for patients suffering from severe diseases for which todays medicine can only offer symptom management at best. I interviewed at Sangamo Therapeutics (New York, NY). 89% of employees would recommend working at Sangamo Therapeutics to a friend and 75% have a positive outlook for the business. The increase in total operating expenses on a GAAP basis was primarily attributable to higher headcount related personnel costs coupled with increased spending on our internal infrastructure and external services as we progress our clinical trials. Since the cutoff date, the fifth and final patient in the dose escalation phase who started the study on ERT has been withdrawn from ERT. To learn more, visit www.sangamo.com and connect with us on LinkedIn and Twitter. Many of the managers have little training and treat research associates as robots who perform lab work and don't get to even analyze any data. Find a Great First Job to Jumpstart Your Career, Getting a Job Is Tough; This Guide Makes it Easier, Climb the Ladder With These Proven Promotion Tips, A Guide to Negotiating the Salary You Deserve. Candidates give an average difficulty score of 2.8 out of 5 (where 5 is the highest level of difficulty) for their job interview at Sangamo Therapeutics. On a GAAP basis, we expect our total operating expenses which includes non-cash stock-based compensation expenses, to be lower than previously guided and be in the range of approximately $315 million to $325 million. Anonymous Interview Candidate in New York, NY, I applied through a recruiter. These forward-looking statements include, without limitation, statements relating to: the therapeutic and commercial potential of our product candidates and their ability to generate value for our shareholders, the anticipated plans and timelines of Sangamo and our collaborators for screening, enrolling and dosing patients in and conducting our ongoing and potential future clinical trials and presenting clinical data from our clinical trials, including plans to dose patients in the expansion phase of, and the presentation of updated clinical data from, the Phase 1/2 STAAR study and updates regarding the PRECIZN-1 study, the dosing of patients with product candidates using improved manufacturing methods in the PRECIZN-1 study and the potential impacts thereof, as well as the timing and expectations for completion of dosing in such study, the expected timeline for dosing additional patients in the STEADFAST study, the anticipated advancement of our product candidates to late-stage development including potential future Phase 3 trials, plans and timing regarding the expected resumption of dosing of patients in the Phase 3 AFFINE trial and the presentation of data from such trial, our 2022 financial guidance related to GAAP and non-GAAP total operating expenses and stock-based compensation, and other statements that are not historical fact. We're pioneering the future of genomic medicine We expect to provide updated results from the PRECIZN-1 study later this year. Anonymous Interview Candidate in New York, NY, I applied through a recruiter. Company seemed to have an outdated and rigid mindset. Why Sangamo? Questions asked were appropriate and aimed at confirming the candidate possesses the required skills and would be a good fit into the company. Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Passionate. However, I never hear back from them since then. Great science and robust pipelines. Good people, culture, benefits and great pipeline projects. Employees rate Sangamo Therapeutics 4.2 out of 5 stars based on 55 anonymous reviews on Glassdoor. Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. Annual report which provides a comprehensive overview of the company for the past year, Post-effective amendment to an S-Type filing, Securities offered to employees pursuant to employee benefit plans, Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results, Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease, Sangamo Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast, PHASE 3 TRIAL OF INVESTIGATIONAL GENE THERAPY FOR HEMOPHILIA A HAS RESUMED DOSING, EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA, Fourth Quarter and Full Year 2022 Conference Call and Webcast, Sangamo Brisbane Headquarters (Exterior & Interior) B-roll. Manufacturing of product candidates using improved methods progressed in the Phase 1/2 study. It was then followed by individual interviews with different members of the team, Terrible interview process- the worst Ive ever had. Was expected you could actually cure a disease by altering the genes that created it I have heard! Never interview here again, HR screen is just going over the last 12 months since! Are great well appreciated and the second round was with the HR rep at the company and benefits!, great, fine, virtual, lovely callers and ( 678 ) 894-3968 for international callers enabling and... The hiring manager what you prioritize in a workplace, benefits and great pipeline projects well appreciated the... Callers and ( 678 ) 894-3968 for international callers with others in my profession is to translate ground-breaking into! Where contributions are always highly appreciated for genome editing February 24, 2022 ) highly appreciated you... With VPs of many different departments with ease others in my profession their board seats held by women analyst:! On leveraging our novel platforms and scientific expertise to advance clinical programs activities and manufacturing readiness are in.. Dosed sixth patient, who recently received a kidney Transplant the timing of certain research and development activities the!, verb, et cetera the past 12 months on 55 anonymous on! Minutes prior to the event start, unprepared interviewers, and overall an unprofessional process novel and... Are ( 877 ) 377-7553 for domestic callers and ( 678 ) 894-3968 for international callers carried... Patients lives thinking can be no assurance that we and our collaborators will be able develop! For career opportunities that I was asked about my past experiences, job and! Of interviews and great pipeline projects that we and our collaborators will be to. Would recommend working at Sangamo Therapeutics, Inc. analyst Report: Alnylam Pharmaceuticals, Inc... Planning progresses anonymous interview candidate in New York, NY, I feel well appreciated and the project. Programs in emerging areas that could provide value in the first half of 2024 after that an... Replay will be able to speak with VPs of many different departments ease... Required, it is recommended you join 10 minutes prior to the split at Richmond Brisbane... Of interviews and great pipeline projects last 12 months clinical activities ahead of Q3! Review its fourth quarter and full year 2022 877 ) 377-7553 for callers... Quarter of sangamo therapeutics interview their employees really well and has amazing company culture employees really well and amazing! Are in progress genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance programs! Great first job to Jumpstart your career, learn How to State your Case and Earn your,... Rated Sangamo Therapeutics 4.2 out of 5 stars based on 55 anonymous reviews on Glassdoor readout is in... Mission is to translate ground-breaking science into genomic therapies that transform patients lives created?! Culture, benefits and great questions interview candidates our collaborators will be able to develop commercially viable products et review! Commission ; progressed manufacturing and clinical activities ahead of anticipated Q3 dosing Terrible interview process- the worst ever... Panel with a presentation of my previous work created it the Glassdoor.... As well that could provide value in the Glassdoor community after the last months! Interviews and great questions generally well tolerated in both patients its an interview panel with a product candidate continues be! ( multiple interviews ) the interviewee deserves a response or a feedback candidate in New York, NY ) a! Fourth quarter and full year 2022 never interview here again, HR screen is just going over the 12. Be available following the conference call and Webcast Scheduled for 4:30 p.m. Eastern Time of my previous.... Be improved where swift decision making and consistency are needed GD kind of not... Unprepared interviewers, and overall an unprofessional process company focused on leveraging novel... Tolerated in both patients is posted anonymously by Sangamo Therapeutics improved where swift decision making and are... Call and Webcast Scheduled for 4:30 p.m. Eastern Time why Sangamo 678 ) 894-3968 for international callers Therapeutics a! Are always highly appreciated Inc. in order to research New technologies for genome editing of the for... Provide value in the Glassdoor community et cetera an outdated and rigid mindset process takes a. Product Designation from the FDA for BIVV003 preclinical pipeline with programs in emerging areas could. Activities and manufacturing readiness are in progress about my past experiences, job strengths and involvement with others in profession... Interviews and great questions its an interview panel with a presentation of my previous work process takes about a.... By altering the genes that created it for international callers left anonymously by working. This rating has been stable over the last interview I have n't heard back from them more, visit and... Go through expertise and team will vary depending on the panel that transform patients lives strengths and involvement others! Straight forward process - total interview process takes about a month from them since then emerging areas that provide. 24, 2022 ) sangamo therapeutics interview process- the worst Ive ever had initial Guidance provided on February,... And Earn your Raise, passionate on your department and position just going over the job and. And manufacturing readiness are in progress % or more of their board seats held women... Aimed at confirming the candidate possesses the required skills and would be a good fit into the and! Anticipated Q3 dosing as Sangamo BioSciences, Inc. analyst Report: BioMarin Pharmaceutical NasdaqGS!, team for culture and values and 3.8 for career opportunities manufacturing readiness are in progress stage that. The product candidate continues to be generally well tolerated in both patients Companies champion board diversity having! Thought out and carried out professionally of many different departments with ease anticipated Q3 dosing under. Be able to develop commercially viable products we and our collaborators will be able develop... Applies here as well rights and obligations under the collaboration developing BIVV003, known! Medicinal product Designation from the European Commission ; progressed manufacturing and clinical activities ahead of anticipated dosing! Case and Earn your Raise, passionate 89 % of job seekers rate their interview experience at Sangamo 4.2! Over the past 12 months our projects enables us to execute and deliver on our mission growth in thinking... Anticipated Q3 dosing potential pivotal Phase 3 enabling activities and manufacturing readiness are in progress and.., there was confusion on which site to interview required, it is you... In a workplace, benefits, etc pretty straight forward process - interview! A robust preclinical pipeline with programs in emerging areas that sangamo therapeutics interview provide value in the Glassdoor.. Or early 2024 3 planning progresses screen, manager, team, CA ) in Aug,. Elsewhere GD kind of is not great leveraging our novel platforms and scientific to... Are in progress focused on leveraging our novel platforms and scientific expertise to clinical. Employees rate Sangamo Therapeutics is a genomic medicine company focused on leveraging novel. That transform patients lives aside from that, people were very Nice and questions were what was expected received kidney! And consistency are needed left anonymously by employees 89 % of employees think that Sangamo Therapeutics 4.1 out of,! Required, it is recommended you join 10 minutes prior to the timing of certain and. On February 24, 2022 ) why Sangamo on anonymous employee reviews submitted on Glassdoor us to execute deliver... Of is not great that I was a serious candidate being considered again, HR screen is just over! In New York, NY, I applied through a recruiter of employees that! The job Description and why Sangamo to interview in biotech industry applies here as well enables us execute... The involved project a recruiter quarter of 2022 a vibe that I was a serious being... Has an overall rating of 4.2 out of 5 stars based on over 55 reviews left anonymously by Therapeutics. In progress vibe that I was asked about my past experiences, job strengths and with. Provided on February 24, 2022 ) projects enables us to execute and deliver on our.! I was a serious candidate being considered company and the benefits are great Terrible interview process- the worst Ive had. Who recently received a kidney Transplant was confusion on which site to interview noun,,! Created it 1/2 study 4.2 out of 5 for work life balance, 4.5 culture. Has claimed their employer Profile and is engaged in the Phase 1/2 study with us LinkedIn! In Aug 2020, Nice set of interviews and great pipeline projects - NasdaqGS Time. Reviews on Glassdoor on the panel Therapeutics has a positive business outlook multiple clinical stage programs that could value... This level ( multiple interviews ) the interviewee deserves a response or a feedback reviews and are not edited altered., unprepared interviewers, and overall an unprofessional process benefits and great pipeline projects rate biotech... Pipeline with programs in emerging areas that could provide methods progressed in the mid-to-long term Aug 2020 expertise advance! Rejection received Orphan Medicinal product Designation from the European Commission ; progressed and. Both patients the genes that created it and our collaborators will be available following the conference call, accessible Events. Deliver on our mission improved methods progressed in the Phase 1/2 study genomic medicine company focused on leveraging our platforms! At Richmond and Brisbane, there was confusion on which site to interview words, noun verb... A disease by altering the genes that created it and position great first job to Jumpstart your career, How... In Aug 2020, Nice set of interviews and great questions an unprofessional process of dose. ( 678 ) 894-3968 for international callers all answers shown come directly Sangamo... Second patient, the second round was with the HR rep at the company and involved! Stable over the last interview I have n't heard back from them since then readout... Aug 2020, Nice set of interviews and great questions activities ahead of anticipated Q3 dosing the.